Slingshot members are tracking this event:
Phase 3 Data of Prostvac for Prostate Cancer Due Second Half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
"The company maintains its previous guidance that full data is expected within this year, albeit in the second half of 2017, with the third interim analysis likely to occur around mid-2017. This estimate is based on a decline in the number of average monthly events currently seen in the PROSPECT study."
Slingshot Insights Explained
Sep 14, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Prostvac, Phase 3 Final Data, Prostate Cancer, Cancer immunotherapy